Retatrutide, a experimental dual agonist of the GLP-1 binding site and glucose-dependent secreted polypeptide (GIP) binding site , is showing promising data in early clinical trials . Recent research https://shopretatrutidepeptide.com/retatrutide-research-knowledge-hub/